CIK 2081668
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 100.00% | 4 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | CYTK | CYTOKINETICS INC | Health Care | 37.40% |
| 2 | BCAX | Bicara Therapeutics Inc. | Health Care | 27.02% |
| 3 | BCRX | BIOCRYST PHARMACEUTICALS INC | Health Care | 21.19% |
| 4 | BHVN | Biohaven Ltd. | Health Care | 14.38% |
4/4 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 100.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 21% of book weight classified — the grid is NOT representative of the whole book.
Classified: 21.2% of book weight (1/4 names) · unclassified 78.8%: CYTK, BCAX, BHVN. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| CYTKCYTOKINETICS INC | — | — | — | — | 980K | 980K | $65M |
| BCAXBICARA THERAPEUTICS INC | — | — | — | — | 1.3M | 2.4M | $47M |
| BCRXBIOCRYST PHARMACEUTICALS INC | — | — | — | — | 3.8M | 3.8M | $37M |
| BHVNBIOHAVEN LTD | — | — | — | — | 2.9M | 2.9M | $25M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
